Markers of fibrinolytic potency and clotting activation in stable angina pectoris: Role of urokinase, assessment of atrioventricular differences and correlation with coronary patency

Fibrinolysis and Proteolysis

Volumn 13, Issue 3, 1999, Pages 133-138

  Paramo U A ^a,b   Panizo, C ^a   Montes, R ^a   Orbe, J ^a   Alegria E ^b   Martinez Caro D ^b   Dooijewaard, G ^c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; UROKINASE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CORONARY BLOOD VESSEL; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; FIBRINOLYSIS; GRAFT PATENCY; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOGENESIS;

EID: 0032793026     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(99)90100-5     Document Type: Article

References (34)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-250.
2. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
3. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res 1993; 70: 1-38.
4. Van de Loo J. Circulating factors of the hemostatic systems as indicators of increased or reduced coronary risk. Br J Haematol 1995; 91: 777-782.
5. Nichols AB, Owen J, Kaplan KL, Sciacca RR, Cannon PJ, Nossel HI. Fibrinopeptide A, platelet factor 4, and β-thromboglobulin levels in coronary heart disease. Blood 1982; 60: 650-654.
6. Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial infarction. Acta Med Scand 1987; 221: 149-153.
7. Gram J, Jespersen J. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction. Thromb Haemost 1987; 57: 137-139.
8. Hamsten A, de Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
9. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157-161.
10. ECAT Angina Pectoris Study Group. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
11. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-2063.
12. Oseroff A, Krishnamurti C, Hasset A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989; 113: 88-93.
13. Shammas NW, Cunningham MJ, Pomerantz RM, Francis CW. Markers of hemostatic activation in affected coronary arteries during angioplasty. Thromb Haemost 1994; 72: 672-675.
14. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106.
15. Pelzer H, Schwarz A, Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-159.
16. Montes R, Páramo JA, Anglés-Cano E, Rocha E. Development and clinical application of a new ELISA assay to determine plasmin-α2-antiplasmin complexes in plasma. Br J Haematol 1996; 92: 979-985.
17. Korninger C, Speizer W, Wojta J, Binder RR. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1983; 31: 427-436.
18. Páramo JA, Alfaro MJ, Rocha E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor: relationship to deep venous thrombosis and influence of prophylaxis. Thromb Haemost 1985; 54: 713-716.
19. Binnema D, van Iersel J, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986; 43: 569-577.
20. Van Hinsberg V, van den Berg E, Fiers W, Dooijewaard G. Tumor necrosis factor induced the production of urokinase-type plasminogen activator by human endothelial cells. Blood 1990; 75: 1991-1998.
21. Meade TW, Ruddoc K, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
22. Rifón J, Páramo JA, Prosper F, Collados MT, Sarrá J, Rocha E. Thrombin-antithrombin complexes and prothrombin fragment 1+2 in aorto-coronary bypass surgery: relation to graft occlusion. Hematol Pathology 1994; 8: 35-42.
23. Van Hulsteijn H, Kolff J, Briët E, van der Laarse A, Bertina R. Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction. Am Heart J 1984; 107: 39-45.
24. Tahara A, Kohno M, Yanagi S et al. Circulating immunoreactive endothelin in patients undergoing percutaneous transluminal coronary angioplasty. Metabolism Clin Exp 1991; 40: 1235-1237
25. Owen J, Laszlo-Hunter M, Williams JK, Adams M. Thrombin activity induced by ballon angioplasty of the coronary artery in Macaca Facicularis (cynomolgus monkey). Blood Coag Fibrinol 1990; 1: 505-507
26. Thompson SG, Kienast J, Pyke SDM, Haverkate F, va de Loo JLW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641.
27. Kienast J, Thompson SG, Raskino C et al. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost 1993; 70: 550-553.
28. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
29. Ridker PM, Hennekens CM, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943.
30. Spannagl M, Dooijewaard G, Dietrich W, Kluft C. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass. Thromb Haemostas 1995; 73: 825-828.
31. Páramo JA, Colucci M, Collen D, Van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ 1985; 291: 573-574.
32. Rocha E, Páramo JA. The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1. Fibrinolysis 1994; 8: 294-303.
33. Ring ME, Vecchione JJ, Fiore LD et al. Detection of intracoronary fibrin degradation after coronary balloon angioplasty. Am J Cardiol 1991; 67: 1330-1334.
34. Carmeliet P, Schoonjans L, Kieckens L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424.